HOUSTON, Jan. 8, 2015 /PRNewswire/ -- OrthoAccel® Technologies, Inc. announced today that it closed on a $5 million equity financing. OrthoAccel Technologies, manufacturer of AcceleDent®, the first and only noninvasive FDA-cleared, Class II medical device that speeds up orthodontic treatment by as much as 50 percent, continues to raise capital to expand its sales force and support its rapid, dynamic growth.
This financing announcement, which coincides with a public filing with the Securities and Exchange Commission, comes as AcceleDent is now available in more than 2,000 orthodontic locations in the U.S.
“We appreciate our capital partners for propelling the next phase of our market expansion and for the confidence they’ve placed in our strategic marketing and sales initiatives,” said Michael K. Lowe, president and CEO of OrthoAccel. “Our rapid market adoption and growth over this past year has solidified OrthoAccel’s position as the leader of accelerated orthodontics, and we anticipate another high growth year ahead as more consumers and orthodontists learn about AcceleDent.”
Lowe adds that stockholders, including equity investors HealthpointCapital and S3 Ventures, remain enthusiastic about OrthoAccel’s growth, rapid market adoption and high level of patient satisfaction. In a recent independent survey, 100 percent of patients reported that AcceleDent is easy to use and that they were satisfied with their experience using the technology. The overwhelming majority of patients also said they would recommend AcceleDent to a family member or friend.
Orthodontists and staff members interested in learning more about AcceleDent, or how to offer the technology at their practice, can locate an OrthoAccel sales representative at AcceleDent.com/orthodontists or call 866-866-4919.
About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the development, manufacturing and marketing of products to enhance dental care and orthodontic treatment. OrthoAccel developed and sells AcceleDent® the first FDA-cleared clinical approach to safely accelerate orthodontic tooth movement by applying gentle micropulses via SoftPulse Technology® as a complement to existing orthodontic treatment. More information can be found at acceledent.com and acceledent.co.uk or requested via info@orthoaccel.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orthoaccel-technologies-inc-secures-5-million-equity-financing-to-continue-rapid-growth-300017849.html
SOURCE OrthoAccel Technologies, Inc.
Help employers find you! Check out all the jobs and post your resume.
